Abstract
Low prevalence of <scp>IgG</scp> antibodies to <scp>SARS‐CoV</scp>‐2 in cancer patients with <scp>COVID</scp>‐19
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have